Q-omics provides the consensus-scored VENTXP4 profile across patient tissues and cancer cell-line models. VENTXP4 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, VENTXP4 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, VENTXP4 RNA expression shows 5,679 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, KIRC, and STAD as cancer lineages where VENTXP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VENTXP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VENTXP4 survival associations across molecular data types. VENTXP4 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VENTXP4 RNA expression–survival associations across cancer types. High VENTXP4 expression shows unfavorable associations in CESC, PCPG, ESCA, LUSC, KICH and THCA. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for VENTXP4 RNA expression.
This table summarizes VENTXP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for VENTXP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VENTXP4 shows higher tumor expression in KIRC. The KIRC box plot shows higher VENTXP4 RNA expression in tumor versus normal tissue (log2 FC = +0.005, t-test p = .023).
This table shows molecular features associated with VENTXP4 in patient tissues and cancer cell lines. In patient samples, VENTXP4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
